APOE and Alzheimer disease: Contrarily, an earlier phase III, randomized, double-blinded placebo-controlled study of extended-release RSG (RSG XR) with prospective stratification by APOE4 status was conducted to confirm the efficacy and safety of RSG XR in mild to moderate AD showed no benefit with the use of RSG XR [145].